Getinge‘s (PINK:GETI B) medical subsidiary Maquet Cardiovascular said today it expanded a patent infringement suit against Saphena Medical and former employee Dr. Albert Chin, adding 2 specific actions taken by the defendants to the case.
The amended complaint, originally filed on Dec. 16 in the United States District Court for the Northern District of California, addresses the application for and receipt of a patent for an invention which originated at Maquet, the company said.
The company alleges that while employed at Maquet, Dr. Chin had access to confidential work done by other Maquet employees on endoscopic vessel harvesting devices and techniques, and that Dr. Chin filed a patent application for such a device after leaving the company.
The complaint also includes a claim accusing Saphena of false advertising in marketing the Venapax System, including false, misleading comparisons of the device to Maquet’s devices, the company said. The amended complaint seeks an injunction, as well as Saphena’s profits and the cost of the suit to remedy the false advertising.
Last October, In October, Maquet announced issues with bacterial contamination associated with its surgical heater-cooler units, according to a field safety notice. The warning affected its HCU 20, HCU 30 and HCU 40 heater-cooler units and its HU 35 heater unit.
The company said that it, along with the national competent authorities in multiple countries, have received reports of mycobacterial contamination in the system water used by heater and heater-cooler devices.